Redeye updates its estimates after Sleep Cycle’s Q4 2023 report, which came in slightly lower on sal...
Growth remains soft while we wait for new releases EBIT ests.
Redeye comments on Better Collective’s announcement of preliminary 2023 revenue and EBITDA which are...
Fortsatt press på den organiska tillväxten… Med en kombination av accelererande nedstängning av kopp...
Redeye endorses yesterday's promising effect signal in 6 out of 8 patients followed for at least 3 m...
Redeye sees only minor deviations in the Q4 numbers vs our expectations.
Innofactor’s Q4 was in line with expectations. Continued uncertainty reduces visibility going into 2...
The outlook for 2024 looks brighter after the tough 2023.
Redeye states that the report was below expectations on sales and profit.
Sales235m (-19% vs. ABGSCe), adj. EBITA 16m (-14% vs.
Redeye updates its estimates and fair value range for Enviro following the final investment decision...
Sales +7% vs. ABGSCe, EBIT +18% vs. ABGSCe Organic growth of +3%, better than ABGSCe -5% Order booki...
Redeye provides its initial comments on Catella's Q4 2023 report, which came in below our forecasts.
Q4 EBIT of SEK 8m vs. ABGSC at 57m and cons. at SEK 66m AUM down 4% q-o-q, driven by FX and negative...
G5 reported weaker than expected growth in Q4 2023 and while recent and upcoming game launches suppo...
Q4 sales +41% y-o-y, +6% vs ABGSCe 111 units started units, 1,182 units in ongoing production GP mar...
Redeye comments on Maximum Entertainment ahead of its Q4-results (due 15 February) where we expect s...
We lower '23e-'25e adj. EBITA by 6-2% Q4 macro data slightly worse than Q3 '24e EV/EBITA of just bel...
Redeye provides its view of Active Biotech's fourth quarter report of 2023 and updates it base case.
Fiskars' Q4 was bang in line with consensus expectations (LSEG Data & Analytics).
